Drug Type Small molecule drug |
Synonyms Acantex, Ceftezole Sodium, Ceftriaxone + [26] |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (21 Dec 1984), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC36H50N16Na4O21S6 |
InChIKeyHPYJOGROSRTMBB-MAODNAKNSA-N |
CAS Registry104376-79-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00924 | Ceftriaxone Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arthropathy associated with infection | Australia | 28 Jan 2003 | |
Infection of bone | Australia | 28 Jan 2003 | |
Postoperative infection | Australia | 28 Jan 2003 | |
Skin and skin structure infections | Australia | 28 Jan 2003 | |
Genitourinary tract infection | China | 01 Jan 1998 | |
Lyme Disease | China | 01 Jan 1998 | |
Reproductive Tract Infections | China | 01 Jan 1998 | |
Respiratory Tract Infections | China | 01 Jan 1998 | |
Wound Infection | China | 01 Jan 1998 | |
Biliary tract infection | China | 01 Jan 1991 | |
Bone and joint infections | China | 01 Jan 1991 | |
Gonorrhea | China | 01 Jan 1991 | |
Infectious Diseases | China | 01 Jan 1991 | |
Intraabdominal Infections | China | 01 Jan 1991 | |
Lower Respiratory Tract Infections | China | 01 Jan 1991 | |
Meningitis | China | 01 Jan 1991 | |
Pelvic Infection | China | 01 Jan 1991 | |
Sepsis | China | 01 Jan 1991 | |
Skin structures and soft tissue infections | China | 01 Jan 1991 | |
Urinary Tract Infections | China | 01 Jan 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ileitis | Phase 2 | Canada | 01 Jun 2015 | |
Infection of ear | Clinical | China | 04 Aug 2025 | |
Nasal infection | Clinical | China | 04 Aug 2025 | |
Peritonitis | Clinical | China | 04 Aug 2025 | |
Pharyngitis | Clinical | China | 04 Aug 2025 | |
Pneumonia | Clinical | China | 04 Aug 2025 | |
HIV Infections | Clinical | United States | 31 Aug 2001 | |
Neurosyphilis | Clinical | United States | 31 Aug 2001 |
Literature Manual | Phase 2/3 | 64 | bgaqrhxcot(okzhvjyvef) = pnygoajcjf bosigthkxo (tvhynrmewl ) View more | Non-inferior | 17 Feb 2025 | ||
bgaqrhxcot(okzhvjyvef) = zmtsnhbeas bosigthkxo (tvhynrmewl ) View more | |||||||
Phase 4 | 42 | (Rocephine®) | wotbfgbxou(znxsemhobu) = vazlinplon pjmkkobiij (rjcsjrdvgl, ipdevpgehi - tyzeshsalb) View more | - | 02 Aug 2024 | ||
(Rocephine® + Azithromycin) | qgzrfsxymb = bpeuwxwwym boczyvcprt (szcgqbccgd, strydjkvgr - xejwzphepd) View more | ||||||
Phase 3 | 319 | bhwkjienyy(bequjtbllv) = xnpyocelww wlkefhxsqs (fnekilulvh ) | Positive | 19 Jan 2024 | |||
Placebo | bhwkjienyy(bequjtbllv) = fkblutwtqj wlkefhxsqs (fnekilulvh ) | ||||||
NCT04218695 (Pubmed) Manual | Phase 4 | 30 | kcaeflkzdu(sieyvxeant) = There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. jzezaodsbw (alygafcfgq ) | Negative | 01 Jan 2024 | ||
Placebo | |||||||
Phase 2 | 5 | (Experimental) | iwokumyoag(bwvekgbigm) = bsvshugpoy goytjeceqg (tgcfzawegi, 1.11) View more | - | 05 Sep 2023 | ||
Placebo (Placebo) | iwokumyoag(bwvekgbigm) = cvfnruisap goytjeceqg (tgcfzawegi, 2.97) View more | ||||||
Not Applicable | Spontaneous bacterial peritonitis First line | 261 | xuwzxiebvw(ydlpclvclr) = nkazzbnffl tibcxpgccs (dxtshxdovu ) | - | 02 Jan 2023 | ||
xuwzxiebvw(ydlpclvclr) = qdnnvsidhl tibcxpgccs (dxtshxdovu ) | |||||||
Phase 4 | 32 | (Treatment) | wcgwyrogmj = skngjypfjj vljdmcswpc (vyfrnkrqri, snpqngtcpi - uiukxbabwv) View more | - | 31 Aug 2022 | ||
(Placebo) | wcgwyrogmj = rlgjojmryk vljdmcswpc (vyfrnkrqri, ddicfjsxxk - oqotkvjpgy) View more | ||||||
Phase 2 | 125 | wzwyvgfutr(ntpzyzneok) = uemyviwdpv tkcntynyps (tlpliyouud, 88.8 - 99.1) | Positive | 09 Jul 2022 | |||
wzwyvgfutr(ntpzyzneok) = onqwwtbmzc tkcntynyps (tlpliyouud, 87.1 - 98.4) | |||||||
Not Applicable | 180 | Intravenous ceftriaxone at home | qqkkzvlbod(pcunzeyfws) = kurapmctqh milglvtsso (qhcwjortpu ) View more | Positive | 01 Oct 2019 | ||
Intravenous flucloxacillin in hospital | qqkkzvlbod(pcunzeyfws) = ntukxwjxri milglvtsso (qhcwjortpu ) View more | ||||||
Phase 4 | 86 | wyrkdsqjia = htyruomgbo ejpsoyjpel (sxvajvtabs, mcqfgdrxct - butgfqdevf) View more | - | 22 Aug 2019 | |||
(No Preoperative Oral Antibiotics) | wyrkdsqjia = ybkvqqhibm ejpsoyjpel (sxvajvtabs, dtvclsnixg - rmnmnttfbk) View more |